Casado Javier G, Pawelec Graham, Morgado Sara, Sanchez-Correa Beatriz, Delgado Elena, Gayoso Inmaculada, Duran Esther, Solana Rafael, Tarazona Raquel
Immunology Unit, Department of Physiology, University of Extremadura, Cáceres, Spain.
Cancer Immunol Immunother. 2009 Sep;58(9):1517-26. doi: 10.1007/s00262-009-0682-y. Epub 2009 Mar 4.
Knowledge of the interactions between MHC-unrestricted cytotoxic effector cells and solid tumour cells is essential for introducing more effective NK cell-based immunotherapy protocols into clinical practise. Here, to begin to obtain an overview of the possible universe of molecules that could be involved in the interactions between immune effector cells and melanoma, we analyse the surface expression of adhesion and costimulatory molecules and of ligands for NK-activating receptors on a large panel of cell lines from the "European Searchable Tumour Cell Line and Data Bank" (ESTDAB, http://www.ebi.ac.uk/ipd/estdab/ ) and discuss their potential role in the immune response against this tumour. We show that most melanoma cell lines express not only adhesion molecules that are likely to favour their interaction with cells of the immune system, but also their interaction with endothelial cells potentially increasing their invasiveness and metastatic capacity. A high percentage of melanoma cell lines also express ligands for the NK-activating receptor NKG2D; whereas, the majority express MICA/B molecules, ULBP expression, however, was rarely found. In addition to these molecules, we also found that CD155 (poliovirus receptor, PVR) is expressed by the majority of melanoma cell lines, whereas CD112 (Nectin-2) expression was rare. These molecules are DNAM-1 ligands, a costimulatory molecule involved in NK cell-mediated cytotoxicity and cytokine production that also mediates costimulatory signals for triggering naïve T cell differentiation. The phenotypical characterisation of adhesion molecules and ligands for receptors involved in cell cytotoxicity on a large series of melanoma cell lines will contribute to the identification of markers useful for the development of new immunotherapy strategies.
了解MHC非限制性细胞毒性效应细胞与实体瘤细胞之间的相互作用,对于将更有效的基于NK细胞的免疫治疗方案引入临床实践至关重要。在此,为了初步概述可能参与免疫效应细胞与黑色素瘤相互作用的分子范围,我们分析了来自“欧洲可检索肿瘤细胞系和数据库”(ESTDAB,http://www.ebi.ac.uk/ipd/estdab/ )的大量细胞系上粘附分子、共刺激分子以及NK激活受体配体的表面表达情况,并讨论它们在针对该肿瘤的免疫反应中的潜在作用。我们发现,大多数黑色素瘤细胞系不仅表达可能有利于其与免疫系统细胞相互作用的粘附分子,还表达可能增加其侵袭性和转移能力的与内皮细胞相互作用的分子。高比例的黑色素瘤细胞系还表达NK激活受体NKG2D的配体;然而,大多数表达MICA/B分子,ULBP表达则很少见。除了这些分子,我们还发现大多数黑色素瘤细胞系表达CD155(脊髓灰质炎病毒受体,PVR),而CD112(Nectin-2)表达罕见。这些分子是DNAM-1的配体,DNAM-1是一种参与NK细胞介导的细胞毒性和细胞因子产生的共刺激分子,也介导触发初始T细胞分化的共刺激信号。对大量黑色素瘤细胞系上参与细胞毒性的受体的粘附分子和配体进行表型特征分析,将有助于识别对开发新免疫治疗策略有用的标志物。